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Background: Patients who require dialysis are at high risk for cardiovascular mortality, which may be
improved by mineralocorticoid receptor antagonists (MRAs).
Study Design: Systematic review and meta-analysis of randomized controlled trials.
Setting & Population: Adults undergoing long-term hemodialysis or peritoneal dialysis with or without heart
failure.
Selection Criteria for Studies: Randomized controlled trials evaluating an MRA in dialysis and reported at
least one outcome of interest.
Intervention: Spironolactone (8 trials) or eplerenone (1 trial) compared to placebo (7 trials) or standard of
care (2 trials).
Outcomes: Cardiovascular and all-cause mortality, hyperkalemia, serum potassium level, hypotension,
change in blood pressure, and gynecomastia.
Results: We identified 9 trials including 829 patients. The overall quality of evidence was low due to
methodologic limitations in most of the included trials. The relative risk (RR) for cardiovascular mortality was
0.34 (95% CI, 0.15-0.75) for MRA-treated compared with control patients. The RR for all-cause mortality was
0.40 (95% CI, 0.23-0.69). The RR for hyperkalemia for MRA treatment was 3.05 (95% CI, 1.21-7.70).
Sensitivity analyses demonstrated wide variability in RRs for cardiovascular mortality, all-cause mortality,
and hyperkalemia, suggesting further uncertainty in the confidence of the primary results.
Limitations: Trial quality and size insufficient to robustly and precisely identify a treatment effect.
Conclusions: Given the uncertainty of both the benefits and harms of MRAs in dialysis, large high-quality
trials are required.
Am J Kidney Dis. 68(4):591-598. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Quach et alreceptor antagonists (MRAs), such as spironolactone
or eplerenone, reduce mortality and hospitalizations
in patients with heart failure with reduced ejection
fraction.6,7 However, there is less certainty about
whether MRAs are beneﬁcial in patients with heart
failure with preserved ejection fraction.8 Given that
patients who require dialysis may develop heart fail-
ure with or without preserved ejection fraction and
that the mechanism by which heart failure occurs
in patients who require dialysis may differ from that
in non2dialysis-dependent patients, it is unclear
whether MRAs will beneﬁt patients who require
dialysis. Furthermore, the use of MRAs is frequently
limited by hyperkalemia in patients with non2
dialysis-dependent chronic kidney disease and it is
uncertain whether patients who require dialysis are
similarly affected.9
Given that the potential beneﬁts and risks of the use
of MRAs in patients who require dialysis are unclear,
we synthesized data from randomized controlled trials
(RCTs) of MRAs in dialysis patients in a systematic
review and meta-analysis. The primary outcome
for our systematic review was CV mortality, with
secondary outcomes of all-cause mortality, hyper-
kalemia, blood pressure, and adverse events.
METHODS
Search Strategy and Selection Criteria
We developed a comprehensive search strategy to identify
all relevant studies regardless of publication status or language
(Table S1, available as online supplementary material). Using
the Ovid portal, we searched MEDLINE (inception to May
2015), Embase (1974 to May 2015), the Cochrane Central
Register of Controlled Trials (CENTRAL), and the Cumulative
Index to Nursing and Allied Health Literature (CINAHL) from
1982 to May 2015. Further, reference lists of published studies
were screened for citations of interest. Clinical trial registries
(ClinicalTrials.gov, International Standard Randomised
Controlled Trial Number Register, and Japan Controlled Trials)
were reviewed to include any relevant trials that were unpub-
lished. Web of Science and BIOSIS databases were also
reviewed. Titles and abstracts of all studies identiﬁed by our
search strategy were screened in parallel by 2 reviewers (K.Q.
and L.L.). Eligible studies included human participants in RCTs
that compared any MRA to a placebo or standard of care and
reported any of the following outcomes: CV mortality, all-cause
mortality, hyperkalemia, serum potassium level, blood pressure,
and adverse events. Eligible studies or studies in which eligi-
bility criteria were unclear after title and abstract screening
underwent full-text review. Two reviewers (K.Q. and L.L.)
assessed eligibility criteria for all studies identiﬁed for full-text
review. Any disagreements in eligibility were resolved through
consensus or by a third author (M.W.) if consensus was not
reached.
Data Extraction and Quality Assessment
Two authors (K.Q. and L.L.) abstracted data in parallel. Study
characteristics (design and duration), participant characteristics
(age, sex, dialysis vintage, dialysis modality, and comorbid
conditions), therapeutic intervention characteristics (MRA type,
dose, and frequency), outcome characteristics (deﬁnition of592hyperkalemia and deﬁnition of CV mortality), and results were
recorded. In crossover trials, only data from the ﬁrst period were
collected due to limitations in data reporting. The quality of in-
dividual RCTs was evaluated using the Cochrane risk of bias in-
strument, which assesses randomization and allocation
concealment, blinding of individuals involved in the trial,
completeness of follow-up, and reporting of outcomes. Each study
outcome was assigned as “low risk of bias,” “unclear,” or “high
risk of bias.”10
Statistical Analysis
Individual-study relative risks (RRs) and 95% conﬁdence in-
tervals (CIs) were calculated for each study (including one study
that reported hazard ratios [HRs] because the HRs were not
materially different from the RRs) using the full trial population,
consistent with the intention-to-treat principle. Participants with
incomplete follow-up were assumed to not have had an event after
loss to follow-up in the primary analyses. A summary RR estimate
was calculated using the Mantel-Haenszel test and a DerSimonian
and Laird random-effects model.11 The degree of between-study
variability attributable to heterogeneity beyond chance was
calculated using the I2 statistic and Q statistic. Outcomes with I2
levels from 0% to 40% were considered minimally heterogeneous,
consistent with Cochrane Collaboration guidance.12 The GRADE
(Grading of Recommendations Assessment, Development, and
Evaluation) approach was used to assess risk of bias across studies
to provide a level of conﬁdence in estimates of the effect in 4
levels (high, moderate, low, and very low).13
Sensitivity analyses were conducted to explore the potential
impact of losses to follow-up on study outcomes by imputing
event rates for patients with missing outcome status using 2
methods. We imputed the observed risk for the outcome from the
control arms pooled across all trials for all missing outcomes in
each trial. As an alternative approach, we performed a worst-case
scenario that assumed all patients with missing outcome in the
intervention group experienced the outcomes and those in the
control group did not.14 We also repeated meta-analyses excluding
the trial at the highest risk of bias to determine its effects on overall
estimates. This trial was thought at highest risk of bias due to
unclear allocation methodology and concealment, imbalanced
baseline characteristics, and lack of blinding.15,16 Finally, we also
estimated effect estimates using the proﬁle likelihood method,
which considers the uncertainty of the between-studies variance
and may be more reliable than DerSimonian and Laird models in
meta-analyses of small trials.17 A 2-sided P, 0.05 was considered
statistically signiﬁcant. Statistical analyses were performed using
RevMan, version 5.2 (The Nordic Cochrane Centre, Cochrane
Collaboration) and proﬁle likelihood analyses were completed
with Stata, version 12 (StataCorp LP).
RESULTS
Figure 1 shows the steps in study selection for
review. Nine RCTs including 829 participants
were ultimately eligible from 1,085 screened cita-
tions.15,16,18-24
Risk-of-Bias and Quality Assessment
Mortality and hyperkalemia were both graded with
low quality of evidence due to imprecision and the
risk-of-bias assessment imparted by incomplete
ascertainment of outcomes and incomplete follow-up
(Table S2). Across all studies, 17% of patients dis-
continued medication. In the 2 largest and longest
trials, discontinuation of medication and subsequentAm J Kidney Dis. 2016;68(4):591-598
Figure 1. Flow diagram of search selec-
tion. Abbreviation: RCT, randomized
controlled trial.
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Aldosterone Antagonism in Dialysisincomplete follow-up accounted for 32% and 22%
of all patients.15,16 Transfer of participants between
dialysis centers, changes in dialysis modality, and
malignancy were major reasons for discontinuation.
Methods for random sequence generation and allo-
cation concealment were unclear in all except 3 tri-
als.21,22,24 Furthermore, baseline characteristics of
patients in the largest trial were not equally distributed
between groups.15 Seven of the 9 studies were double
blinded,18-24 whereas 2 did not use a placebo in their
comparison group.15,16 One trial reported receiving
funding from an industry partner, but no studies re-
ported industry involvement in protocol development,
analyses, or reporting of results.22
Trial Characteristics
A summary of study characteristics is shown in
Table 1. All 9 trials were published in the English
language in 2005 to 2015. Seven RCTs used a parallel
design,15,16,19-22,24 whereas 2 RCTs used a crossover
design.18,23 Spironolactone was the MRA in 8
trials,15,16,18-21,23,24 and eplerenone, in one.22 Sample
sizes ranged from 8 to 309. Average age and percent
of males of all study participants was 60.2 years and
63.1%, respectively. Five trials included only hemo-
dialysis patients,15,18,20-22 and 4 included only
patients undergoing peritoneal dialysis.16,19,23,24
The target population varied between trials, with
one trial enrolling only patients with reduced ejectionAm J Kidney Dis. 2016;68(4):591-598fraction,19 one excluding patients with symptomatic
heart failure,25 one including only patients already
using 3 antihypertensives,24 and one excluding pa-
tients with diabetes or vascular disease.21 Patients
received dialysis from 3 to 128 months prior to
enrollment. Median duration of follow-up was 6
(range, 0.5-36) months. Use of b-blockers, angio-
tensin receptor blockers, or angiotensin-converting
enzyme inhibitors was permitted in all except one
study.21
CV and All-Cause Mortality
Of 9 trials, 6 contributed mortality data (721 pa-
tients)15,16,19-22 and one had no CV mortality events
and thus was excluded from CV mortality analyses.18
Effects of MRA on CV and all-cause mortality for the
primary and sensitivity analyses are summarized in
Table 2. Compared with controls, the RR of CV
mortality for MRA-treated patients was 0.34 (95% CI,
0.15-0.75; P5 0.008; Fig 2). There was no signiﬁcant
heterogeneity observed for CV mortality (I2 5 0%;
P 5 0.9) and no signiﬁcant evidence of publication
bias (ﬁg a of Item S1). However, the effect of MRAs
was attenuated and results were not statistically sig-
niﬁcant in our sensitivity analyses. Imputation of
the pooled control group event rate for patients lost
to follow-up resulted in an RR of 0.54 (95% CI,
0.28-1.02; P 5 0.06; ﬁg a of Item S1), whereas
the worst-case scenario resulted in an RR of 2.04593
Table 1. Baseline Characteristics of Included Trials
Study Design Sample Sizea Complete F/U Intervention Control
F/U,
mo Mean Age, y Male Sex, % CHF
Dialysis
Type Funding
Gross et al18
(2005)
Crossover 8 8 (100) Spironolactone
50 mg 23/d
Placebo 0.5 53 6 10 38 I: 0%; C: 0% HD Not disclosed
Ito et al16 (2014) Parallel I: 78; C: 80 I: 50 (64); C: 58 (73) Spironolactone
25 mg/d or
eplerenone
50 mg/d
Noneb 24 I: 57.4 6 12.3; C:
55.6 6 14.4
I: 71; C: 73 I: 0%; C: 0% PD Ministry of Health,
Labor and
Welfare of Japan
Matsumoto
et al15 (2014)
Parallel I: 157; C: 152 I: 112 (71); C: 128 (84) Spironolactone
25 mg/d
Noneb 36 I: 67.4 6 12.3; C:
66.7 6 11.2
I: 71.9; C:
59.2
I: 0%; C: 0% HD Not disclosed
Ni et al24 (2014) Parallel I: 40; C: 36 I: 36 (90); C: 34 (94) Spironolactone
25 mg/d
Placebo 12 I: 55.7 6 12.3; C:
54.9 6 14.2
I: 60; C: 58 Not reported HD/PD Not disclosed
Taheri et al20
(2009)
Parallel I: 8; C: 8 I: 8 (100); C: 8 (100) Spironolactone
25 mg 33/wk
Placebo 6 I: 59.5 6 6.5; C:
56.8 6 9.3
I: 63; C: 75 I: 100%; C:
100%
HD Not disclosed
Taheri et al19
(2012)
Parallel I: 9; C: 9 I: 7 (78); C: 9 (100) Spironolactone
25 mg every
other day
Placebo 6 I: 50.7 6 17.4; C:
57.2 6 13.1
I: 56; C: 56 I: 100%; C:
100%
CAPD Isfahan University of
Medical Sciences
Vukusich et al21
(2010)c
Parallel I: 33; C: 33 I: 30 (91); C: 23 (70) Spironolactone
50 mg 33/wk
Placebo 24 I: 60.1 6 5.2; C:
55.6 6 3.6
I: 67; C: 61 I: 10%; C: 4% HD Fondo Ayuda
Investigacion
Universidad Los
Andes
Walsh et al22
(2015)
Parallel I: 77; C: 77 I: 77 (100); C: 77 (100) Eplerenone
50 mg/d
Placebo 3 I: 62.1 6 14.6; C:
63.1 6 13.7
I: 61; C: 64 I: 10%; C: 8% HD CIHR, CANNeCTIN,
CANN-NET,
Pfizer Canada
Yongsiri et al23
(2015)
Crossover 24 20 (83) Spironolactone
25 mg/d
Placebo 4 52.4 6 12.4 40 Not reported CAPD Commission of
Thailand and
Faculty of
Medicine,
Burapha
University,
Thailand
Note: Values for categorical variables are given as number (percentage) or percentage; for continuous variables, as mean 6 standard deviation.
Abbreviations: C, control; CANNeCTIN, Canadian Network and Centre for Trials Internationally; CANN-NET, Canadian Kidney Knowledge Translation and Generation Network; CAPD,
continuous ambulatory peritoneal dialysis; CHF, congestive heart failure; CIHR, Canadian Institutes of Health Research; F/U, follow-up; HD, hemodialysis; I, intervention; PD, peritoneal
dialysis.
aBaseline.
bStandard of care.
cBaseline characteristics reported on 30 I and 23 C patients.
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Table 2. Summary of Efficacy and Safety Outcomes Analyses
Outcome MRA Control RR (95% CI)
CV mortality, n5 5
Intention-to-treat
population
7/329 23/326 0.34 (0.15-0.75)
Control risk scenario 13/329 26/326 0.54 (0.28-1.02)
Worst-case scenario 81/329 23/326 2.04 (0.75-5.56)
Excluding highest risk
of bias
1/94 7/94 0.27 (0.06-1.24)
Profile likelihood 7/329 23/326 0.34 (0.14-0.75)
All-cause mortality, n 5 6
Intention-to-treat
population
16/362 43/359 0.40 (0.23-0.69)
Control risk scenario 26/362 49/359 0.56 (0.36-0.87)
Worst-case scenario 93/362 43/359 2.01 (1.09-3.70)
Excluding highest risk
of bias
4/127 8/127 0.71 (0.24-2.09)
Profile likelihood 16/362 43/359 0.40 (0.22-0.90)
Hyperkalemia, n 5 7
Intention-to-treat
population
18/381 4/374 3.05 (1.21-7.70)
Control risk scenario 18/381 4/374 3.05 (1.21-7.70)
Worst-case scenario 97/381 4/374 9.35 (3.37-25.93)
Excluding highest risk
of bias
13/146 3/142 2.97 (1.02-8.67)
Profile likelihood 18/381 4/374 3.54 (1.95-5.04)
Note: Control risk scenario imputes the overall control group
outcome risk for all participants with missing outcome follow-up,
whereas worst-case scenario imputes an event for all partici-
pants with missing outcome follow-up in the MRA group and no
event for all participants in the control group.
Abbreviations: CI, confidence interval; CV, cardiovascular;
MRA, mineralocorticoid receptor antagonists; RR, relative risk.
Aldosterone Antagonism in Dialysis(95% CI, 0.75-5.56; P 5 0.02; ﬁg b of Item S1).
Furthermore, exclusion of the 2 trials at highest risk of
bias resulted in an RR of 0.27 (95% CI, 0.06-1.24; P5
0.09; ﬁg c of Item S1). Proﬁle likelihood estimates
found the RR for CV mortality to be 0.34 (95% CI,
0.14-0.75).
Compared with controls, the RR of all-cause
mortality for MRA-treated patients was 0.40 (95%
CI, 0.23-0.69; P 5 0.001; Fig 3). There was no sta-
tistical heterogeneity in all-cause mortality observedFigure 2. Forest plot of the effects of mineralocorticoid receptor an
Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
Am J Kidney Dis. 2016;68(4):591-598(I2 5 0%; P 5 0.6). As with CV mortality, the effect
of MRAs on all-cause mortality and statistical sig-
niﬁcance was signiﬁcantly attenuated in sensitivity
analyses that imputed either the control group event
rate or worst-case scenario for patients lost to follow-
up, as did removal of the 2 studies at highest risk
of bias (ﬁgs a-c of Item S2). The RR estimated
using the proﬁle likelihood method was 0.40 (95%
CI, 0.22-0.90).
Hyperkalemia
Hyperkalemia was deﬁned as potassium level . 5
mEq/L in one study,24 $5.5 mmol/L in one study,19
.5.5 mmol/L in 2 studies,20,23 $6.0 mmol/L in 2
studies,18,21.6.0 mmol/L in one study,16$6.5 mmol/L
in one study,15 and.6.5 mmol/L in one study.22 Two
trials did not report any hyperkalemic events and were
excluded from analyses.18,21 In the 7 RCTs including
755 patients, MRA use was signiﬁcantly associated
with hyperkalemia (RR, 3.05; 95% CI, 1.20-7.71;
P 5 0.04; Fig 4). No signiﬁcant heterogeneity
was observed (I2 5 0%; P 5 0.8). One study reported
a mean serum potassium level increase of 0.16 (95%
CI, 0.04-0.28) mmol/L (P 5 0.008) compared to pla-
cebo over 13 weeks,22 whereas another reported an
increase of 0.012 mmol/L per month (P, 0.001) over
24 months.21 Worst-case scenario suggested that if all
patients lost to follow-up in the MRA group developed
hyperkalemia, the RR of hyperkalemia would be 9.35
(95% CI, 3.37-25.93; P , 0.001; Fig S1).
Blood Pressure
Differences in reporting methods precluded meta-
analysis of blood pressure results. Trials noted a
decrease in predialysis systolic blood pressure in
MRA-treated patients that ranged from 1.7 to
11 mm Hg and from 2 to 5.2 mm Hg in control pa-
tients. One trial that measured mean ambulatory blood
pressure observed a signiﬁcant decrease in systolic
(212.5 mm Hg) and diastolic (27.0 mm Hg) blood
pressure after 12 weeks.24 In the 2 trials that reported
hypotensive events, no signiﬁcant difference was
detected between the MRA and placebo groups.16,22tagonists (MRAs) on cardiovascular mortality in dialysis patients.
595
Figure 3. Forest plot of the effect of mineralocorticoid receptor antagonists (MRAs) on all-cause mortality in dialysis patients.
Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
Quach et alOther Adverse Effects
Four studies reported 30 patients who developed
gynecomastia or breast pain in spironolactone-treated
patients, with an overall incidence of 11% in the
MRA groups.15,16,21,24 Only one study compared
events of gynecomastia in the spironolactone
compared to the control group (RR, 5.64; 95% CI,
1.29-24.63; P 5 0.03).16
DISCUSSION
Our systematic review and meta-analysis identiﬁes
MRAs as a potentially beneﬁcial treatment to reduce
CV mortality for dialysis patients. Although risk
lowering appears substantial, data are insufﬁcient to
robustly determine whether MRAs are truly beneﬁcial
for dialysis patients. Furthermore, due to high risk of
bias, losses to follow-up, and inadequate number of
outcomes, there is a substantial risk for hyperkalemia
that may limit widespread use of MRAs in dialysis
patients.
RR reductions for major CV events in non2
dialysis-dependent patients with heart failure treated
with an MRA are 10% to 30% in large RCTs and
meta-analyses.6-8 Our meta-analysis suggested a 66%
RR reduction in dialysis patients, only some of whomFigure 4. Forest plot of the effect of mineralocorticoid receptor a
ations: CI, confidence interval; M-H, Mantel-Haenszel.
596had heart failure. There are several possibilities for the
difference in effect between dialysis-dependent and
non2dialysis-dependent patients.
First, one must acknowledge the likelihood that
the current meta-analysis misestimates the effect of
MRAs in dialysis patients. The misestimation may
arise from either bias or imprecision. The issue of po-
tential bias is particularly important given that the 2
largest trials are considered at the highest risk of bias
due to unclear allocationmethods, lack of blinding, and
incomplete follow-up. The potential for bias is further
underscored by the lack of reported data for some
outcomes in some studies and the degree to which our
results depend on how losses to follow-up are handled.
The possibility that imprecision has resulted in an
overestimate of the effect of MRAs must also be
acknowledged despite the statistical signiﬁcance of our
results. Our estimates are based on only 30 CV mor-
tality events, whereas simulation studies suggest that at
least 300, if not 600, events are necessary to provide
stable estimates of effect.26 A useful way to approach
this issue is to consider the required sample size of
a single trial to detect a plausible treatment effect
under assumptions similar to those observed in the
trials conducted to date. The control event rate is
approximately 3.5 CV deaths per 100 patient-years ofntagonists (MRAs) on hyperkalemia in dialysis patients. Abbrevi-
Am J Kidney Dis. 2016;68(4):591-598
Aldosterone Antagonism in Dialysisfollow-up in a prevalent cohort with all-cause mor-
tality of 6.1 per 100 patient-years (and therefore a risk
for non-CV death of 2.6 per 100 patient-years).
Assuming an HR of 0.75 for CV death, consistent
with MRA use in other trials, and using non-CV death
as a competing risk as suggested by other trials of CV
event reduction in dialysis, one would require at least
2,380 patients (1,190 per group) with a resulting
380 events to achieve 80% power with 2-sided a of
0.05.27 This calculation does not factor in the effects of
nonadherence, loss to follow-up, crossover, and loss to
transplantation.27 Furthermore, detecting an HR of 0.8
under similar conditions would require at least 3,853
patients (1,926 per group) with a resulting 630 events.
Given that most monotherapies for chronic CV disease
are expected to yield only moderate treatment effects,
our current meta-analysis is less than one-third the
required size to make credible inferences despite the
statistical signiﬁcance of the results.
Despite these issues, MRAs are a promising ther-
apy with a strong rationale for efﬁcacy in dialysis
patients and there is reason to believe that MRAs may
be at least as effective in dialysis patients as in pa-
tients with heart failure. Patients with heart failure
after myocardial infarction may have only a short
duration of elevated aldosterone activity, resulting in
a limited time for MRAs to have an effect. In dialysis,
long-term elevations of aldosterone levels (triggered
by the rapid cycling of volume status and serum
potassium) in dialysis patients may create an ongoing
beneﬁt of MRAs.28 It is also possible that dialysis-
dependent patients may tolerate hyperkalemia better
than non2dialysis-dependent patients because of the
frequent monitoring and routine dialysis, which the
latter do not receive and which may mitigate the po-
tential harms of MRAs.
Although evidence suggesting that MRAs beneﬁt
dialysis patients is promising, the potential to cause harm
must be considered. MRA use in non2dialysis-
dependent patients is often limited by hyperkalemia
caused by reduced renal potassium excretion.9 In the
dialysis population, it is unclear how quantitatively
important aldosterone-mediated renal excretion of po-
tassium might be. Given that potassium excretion by
renal tubules requires tubular ﬂow of urine, it seems
unlikely, though not impossible, that it is of major
quantitative importance in most dialysis patients.
Aldosterone may also affect extrarenal potassium
excretion (eg, gastrointestinal, salivary, and perspira-
tion), and the degree to which this is important in the
absence of kidney function is uncertain.29 Therefore,
MRA-mediated hyperkalemia in dialysis patients
may arise from reduced extrarenal excretion. Given
concerns over harm from other drugs that act on the
renin-angiotensin-aldosterone system in dialysis pa-
tients, further studies are required to understand theAm J Kidney Dis. 2016;68(4):591-598safety of MRAs in dialysis patients and how to best
monitor their use.30
Our meta-analysis has several strengths, including
a thorough and comprehensive assessment of the
available literature’s risks of bias and sensitivity
analyses to ensure the ﬁndings were robust. We
demonstrated that qualitative results of the meta-
analysis are highly dependent on the potential out-
comes of participants with incomplete follow-up.
However, the true event rates of participants lost to
follow-up are unpredictable and unlikely to be at
either extreme of our assumptions (ie, no participants
had events or only participants in the treatment group
had events). It is therefore unclear where in the
spectrum of potential results the true treatment effect
may lie. In addition, we demonstrated a substantial
difference between total meta-analysis sample size
and optimal sample size. As such, despite statistical
signiﬁcance, the clinical signiﬁcance of these data
remains uncertain and therefore further studies are
needed to substantiate or refute these results before
any changes to clinical practice or guidelines are
made.
In summary, although small studies suggest that
MRAs may improve patient-important outcomes for
patients who require dialysis, there is insufﬁcient
evidence to support their widespread use. Further-
more, MRAs likely increase the risk for serious
hyperkalemia. Larger trials are required to clarify the
beneﬁt-risk ratio for this potentially important class of
medications in dialysis patients.
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